This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

    Menu

    Close

    HomeAbout NGENLAEfficacySafetyDosingDosingDosing & AdministrationMyNgenla PlanSupport and ServicesSupport and ServicesMaterialsVideosPatient Support
    Prescribing InformationIndication Patient Site
    Patient support

    Pfizer Bridge Program®

    Field Reimbursement
    Colleagues

    NGENLA Access
    for Eligible Patients

    The Pfizer Bridge Program can support patients through their NGENLA treatment journey in many ways

     

    Device training (in-home or
    virtual) by an experienced nurse    		 Assist with understanding
    the insurance process

    Arrange for the first
    shipment from the pharmacy
    and address issues that may
    lead to pharmacy delays or
    treatment interruptions
    Provide eligible patients
    with copay assistance
     
    Scroll left to view table

    Device training
    (in-home or
    virtual) by an
    experienced nurse
     
    Assist with
    understanding
    the insurance
    process
     

    Arrange for the
    first shipment from
    the pharmacy and
    address issues
    that may lead to
    pharmacy delays
    or treatment
     interruptions

    Provide eligible patients with copay assistance
    Enroll patients in the Pfizer Bridge Program Loading Enroll patients in the
    ​​​​​​​Pfizer Bridge Program         Loading

    For more information about the Pfizer Bridge Program, please call 1-800-645-1280, reach out to your Pfizer representative, or visit www.pfizerbridgeprogram.com.

    For more information about the Pfizer Bridge Program, please call 1-800-645-1280, reach out to your Pfizer representative, or visit www.pfizerbridgeprogram.com.

    Pfizer Field Reimbursement colleagues

    Educate health care providers (HCPs) and their staff about reimbursement, access, and coverage in order to help patients gain access to prescribed Pfizer products

    Respond to patient-specific access and reimbursement questions from HCPs and office staff

    Coordinate with the Pfizer Bridge Program about individual patient cases and to discuss reimbursement and coverage developments affecting Pfizer products

     Visit Pfizer RxPathways® to learn more Loading​​​​​​​ Visit Pfizer RxPathways® to
    ​​​​​​​learn more         Loading
    Interim care to help support you on NGENLA*

    If your patient's insurance coverage is delayed or denied due to certain circumstances, the NGENLA Interim Care program may be able to help. Eligible, commercially insured patients enrolled in the NGENLA Interim Care program may receive NGENLA at no cost from 30 days up to a maximum of 180 days depending on the type of coverage delay.† Contact the Pfizer Bridge Program at 1-800-645-1280 for more information.

    Interim care to help support you on NGENLA*
     
    Eligible, commercially insured patients may be able to receive medication at no
    cost*     in certain instances where there is a coverage delay.

    Copay Program

    One simple plan covers copays and deductibles for NGENLA, offering savings UP TO $6,000
    PER YEAR. Eligible patients may pay AS LOW AS $0 per prescription.§

    Interim Care 
    Support

    Eligible commercially insured patients
    receive up to     90 DAYS OF NGENLA AT
    NO COST    * to provide access during
    ​​​​​​​delays in insurance authorization.
    Pfizer Patient
    Assistance Program†
     
    Provides eligible uninsured and
    government-insured patients with
    NGENLA AND SUPPLIES AT
    NO COST    .‡

    Copay Program

    One simple plan covers copays and
    deductibles for NGENLA, offering
    savings UP TO $5,000 PER YEAR.
    ​​​​​​​Eligible patients may pay AS ​​​​​LOW AS
    ​​​​​​​$0     per prescription.§

    Interim Care must be requested by the physician. Patients must meet program criteria to receive the support. Interim care support can range from 30 days to a maximum of 180 days depending on the type of coverage delay. Commercially insured patients only and may not reside in Massachusetts, Michigan, Minnesota, or Rhode Island.Interim Care is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for NGENLA. For patients who experience a delay in insurance coverage while actively pursuing a prior authorization or appeal, coverage may be up to a maximum of 90 days. For patients who experience a delay due to a new to market block, coverage may be up to a maximum of 180 days. Interim Care is not available to patients covered under Medicaid, Medicare, or other federal or state healthcare insurance programs.Copay Program

    One simple plan covers copays and deductibles for NGENLA, offering savings UP TO $6,000 PER YEAR. Eligible patients may pay AS LOW AS $0 per prescription.‡

    Terms and conditions apply.

    By using this copay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:Patients are not eligible to use this card if they are enrolled in a state or federally-funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, or a state prescription drug assistance program. Patient must have private insurance. Offer is not valid for cash-paying patients. Patients are responsible for as little as a $0 monthly copayment based upon program utilization. The value of this copay card is limited to a maximum of $6,000 per calendar year. This copay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. You must deduct the value of this copay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the copay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the copay card, as may be required. You should not use the copay card if your insurer or health plan prohibits use of manufacturer copay cards. This copay card is not valid where prohibited by law. Copay card cannot be combined with any other savings, free trial or similar offer for the specified prescription. Copay card will be accepted only at participating pharmacies. If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer. This copay card is not health insurance. Offer good only in the U.S. (including Puerto Rico, the U.S. Virgin Islands, and Guam). Copay card is limited to 1 per person during this offering period and is not transferable. A copay card may not be redeemed more than once per 30 days per patient. No other purchase is necessary. No membership fee. Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this offer without notice. Offer expires 12/31/2023. For more information, visit our website www.ngenla.com, call 1-800-645-1280 or visit pfizer.com. NGENLA Copay Program, PO Box 220746, Charlotte, NC 28222-0746.

    Contact the Pfizer Bridge Program at 1-800-645-1280 to learn more about the NGENLA Copay Card.

     Efficacy

    Height outcomes comparable to a daily GH with fewer injections.1

     View height outcomes Loading     Safety

    Demonstrated an adverse event profile similar to daily GENOTROPIN®.1

     View safety data Loading     Dosing

    Once-weekly administration with a multidose, prefilled pen.1

     See Instructions for Use Loading    Reference:NGENLA. Prescribing information. Pfizer Inc.; 2023.

    To report an adverse event, please call 1-800-438-1985

    Pfizer for Professionals 1-800-505-4426

    This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

    © 2024 Pfizer Inc. All rights reserved.

    PP-SMT-USA-0370
    You are now leaving this site You are being redirected to the Pfizer Medical Information website for US Health Care Professionals.

    By selecting 'OK' below, you certify that you are a US Health Care Professional and that you have a question regarding a Pfizer Medicine.
    INDICATION NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
    Important Safety Information CONTRAINDICATIONS
    Somatrogon is contraindicated in patients with acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with growth hormones. 

    NGENLA is contraindicated in patients with hypersensitivity to somatrogon or any of its excipients.

    Somatrogon is contraindicated in patients with closed epiphyses.

    Somatrogon is contraindicated in patients with active malignancy due to the risk of malignancy progression. 

    Somatrogon is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.

    Somatrogon is contraindicated in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to the risk of sudden death.

    WARNINGS AND PRECAUTIONS
    Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure has been reported with somatropin. The safety of continuing NGENLA treatment for the approved indication who concurrently develop these illnesses has not been established.

    Severe systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with somatropin. Inform patients and caregivers that such reactions are possible and that prompt medical attention should be sought if allergic reaction occurs.

    There is an increased risk of malignancy progression with somatropin treatment in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment should be completed, prior to instituting therapy with NGENLA. Discontinue NGENLA if there is evidence of recurrent malignancy.

    In childhood cancer survivors who were treated with radiation to the brain/head for their first neoplasm and who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Intracranial tumors, in particular meningiomas, were the most common of these second neoplasms. Monitor all patients with a history of GHD secondary to an intracranial neoplasm while on NGENLA therapy for progression or recurrence of the tumor.

    Because children with certain rare genetic causes of short stature have an increased risk of developing malignancies, thoroughly consider the risks and benefits of starting NGENLA in these patients. If treatment with NGENLA is initiated, carefully monitor these patients for development of neoplasms.

    Monitor patients on NGENLA therapy carefully for increased growth or potential malignant changes of preexisting nevi. Advise patients and/or caregivers to report marked changes in behavior, onset of headaches, vision disturbances, and/or changes in skin pigmentation or changes in the appearance of preexisting nevi.

    Treatment with growth hormone may decrease insulin sensitivity, particularly at higher doses. New-onset type 2 diabetes mellitus has been reported in patients receiving growth hormone. Patients with undiagnosed pre-diabetes and diabetes mellitus may experience worsened glycemic control and become symptomatic. Monitor glucose levels periodically in all patients receiving NGENLA, especially in those with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. Patients with preexisting type 1 or type 2 diabetes mellitus or pre-diabetes should be monitored closely. The doses of antidiabetic agents may require adjustment when NGENLA is initiated.

    Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in patients treated with somatropin. Symptoms usually occurred within the first 8 weeks after the initiation of somatropin therapy. In all reported cases, IH-associated signs and symptoms rapidly resolved after cessation of therapy or a reduction of somatropin dose. NGENLA should be temporarily discontinued in patients with clinical or fundoscopic evidence of IH. If IH is confirmed, restart treatment with NGENLA at a lower dose after IH-associated signs and symptoms have resolved. 

    Fluid retention during NGENLA therapy may occur. Clinical manifestations of fluid retention (eg, edema and nerve compression syndromes including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent.

    Patients receiving growth hormone therapy who have or are at risk for pituitary hormone deficiencies may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of NGENLA treatment. Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism. 

    Undiagnosed/untreated hypothyroidism may prevent an optimal response to NGENLA therapy. In patients with GH deficiency, central (secondary) hypothyroidism may first become evident or worsen during treatment with growth hormone therapy. Therefore, patients should have periodic thyroid function tests and thyroid hormone replacement therapy should be initiated or appropriately adjusted when indicated.

    Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Evaluate pediatric patients with the onset of a limp or complaints of persistent hip or knee pain.

    NGENLA increases growth rate, and progression of preexisting scoliosis can occur in patients who experience rapid growth. Growth hormone treatment has not been shown to increase the occurrence of scoliosis. Monitor patients with a history of scoliosis for disease progression.

    Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared with adults. Consider pancreatitis in patients who develop persistent severe abdominal pain.

    When growth hormone is administered subcutaneously at the same site over a long period of time, lipoatrophy may result. Rotate injection sites when administering NGENLA to reduce this risk.

    There have been reports of sudden death after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. NGENLA is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.

    Serum levels of phosphorus, alkaline phosphatase, and parathyroid hormone may increase with NGENLA therapy. If a patient is found to have abnormal laboratory tests, monitor as appropriate.

    ADVERSE EFFECTS
    Adverse reactions reported in ≥5% of patients treated with NGENLA are injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, and oropharyngeal pain. Health care providers should supervise the first injection and provide appropriate training and instruction for the proper use of all NGENLA devices.    Indication NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

    Please see full Prescribing Information.